Coats disease, is a rare retina condition diagnosed primarily in children. Symptoms may include, eye drift, blurry vision, the appearance of a white or silver looking retina, and retina detachment.…
Emerging evidence, as reported by the American Academy of Ophthalmology, suggests that glycemic surveillance should be considered for all patients undergoing teprotumumab therapy for thyroid eye disease (TED), regardless of…
As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug Lacripep® in the treatment of…
Twelve‑month, real‑world data from a large U.S. registry suggest that faricimab provides effective, durable, and safe treatment for retinal vein occlusion (RVO), reinforcing findings from earlier clinical trials and its…
A new study in Nature Communications and reported by Scienmag.com overturns a central assumption in eye biology by showing that key stem cells for the retina’s blood vessels are not…
A UCLA Health study published on UCLAHealth.org suggests that numbers already used to gauge heart health may also offer an early warning for serious eye disease. Researchers found that a…
In a major advance for patients with the rare eye disease keratoconus, Glaukos has secured U.S. Food and Drug Administration (FDA) approval for Epioxa, an incision-free corneal cross-linking therapy. As…
About 150,000 people with glaucoma across the United States wear contact lenses—and they may soon have access to an even more effective wearable treatment option. According to Medical Device Network,…
According to a story from Valdosta Daily Times, a collaboration between the biotechnology company ReflectionBio® and the nonprofit organization Invincible Vision is taking aim at the rare disease Bietti's crystalline…
Over the last few days, the American Society of Retina Specialists (ASRS) held their Annual Virtual Meeting; coined "2020 Virtual Sessions," professionals converged online to share insights into ophthalmological…
Discovery Phase Drugs for Orphan Eye Diseases IVMED-100- 80- 90 are currently without generic drug names. They are under development for the treatment of orphan eye diseases by iVeena, LLC who has 6…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
